Canada Ditches Moderna Booster For Pfizer Over Myocarditis Risk In Young Men


Canada has become the latest country to recommend that young people – in this case boys and men aged 12 through 29 – should opt for the Pfizer Covid-19 booster shot over Moderna’s Spikevax due to a higher risk of myocarditis.

On Page 7 of Canada’s National Advisory Committee on Immunization’s revised guidelines, the new guidance calls for the Pfizer-BioNTech offering due to “Lower reported cases of myocarditis/pericarditis … compared to Moderna Spikevax.

Canada’s Chief Public Health Officer Dr. Theresa Tam explained the decision in a Friday tweet, noting that “The latest data suggests the rare risk of these events following vaccination with mRNA COVID-19 vaccines (most often seen in males 12-29 yrs) may be lower with Pfizer-BioNTech Comirnaty (30 mcg) compared to Moderna Spikevax (100 mcg) vaccine,” while a “longer interval between 1st & 2nd dose of a primary series results in stronger immune response/higher vaccine effectiveness + may be associated with lower risk of myocarditis &/or pericarditis in teens & young adults.”

The agency still recommends both vaccination and boosters.

Canada joins Germany, France, Finland, Denmark and Sweden in warning young adults to avoid the Moderna jab following evidence of ‘rare but harmful’ side effects. The decision follows recently released data showing that the risk of heart inflammation from Pfizer’s jab “appears to be around five times lesser…compared to Modera’s spikevax jab”, per an opinion published by the HAS.

Here’s a summary of the German PEI data via Reuters:

The German PEI data showed a “report rate” for heart inflammations of 11.71 per 100,000 shots with the Moderna vaccine for men in the 18-29 age group, compared with 4.68 for the Biontech/Pfizer shot. For women, the rate was 2.95 with Moderna and 0.97 with Biontech/Pfizer.

In the 12-17 age group, the rate was 11.41 for males with the Moderna shot compared with 4.81 for Biontech/Pfizer. There was no data provided for females in the lower age group.

In November, Europe’s drug regulator confirmed that it’s investigating Moderna’s mRNA vaccine following six cases of capillary leak syndrome.





Source link